Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: With analysis of liver and kidney signal change on early and delayed imaging

Journal of Magnetic Resonance Imaging

Volumn 11, Issue 6, 2000, Pages 655-664

  Runge, Val M ^a,b   Kenney, Charles M ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Contrast agents; Liver; Liver, abnormalities; Magnetic resonance (MR); MR

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LIVER DISEASE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034078043     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/1522-2586(200006)11:6<655::AID-JMRI12>3.0.CO;2-H     Document Type: Article

References (26)

1. Paley MR, Ros PR. MR imaging of the liver - a practical approach. Magn Reson Imaging Clin N Am 1997;5:415-429.
2. Giovagnoni A, Paci E. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am 1996;4:61-72.
3. Van Beers BE, Gallez B, Pringot J. Contrast-enhanced MR imaging of the liver. Radiology 1997;203:297-306.
4. Rosati G, Pirovano G, Spinazzi A. Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994;29(suppl 2):S183-185.
5. Spinazzi A, Pirovano G, Ratcliffe G, et al. Multicenter testing of gadobenate dimeglumine in magnetic resonance imaging of focal liver disease. Acad Radiol 1996;3(suppl 2):S415-416.
6. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 1998;8:862-867.
7. Spinazzi A, Lorusso V, Pirovano G, et al. Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5(suppl 1):S86-89; discussion S93-94.
8. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 1997;7:275-80.
9. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 1996;199:513-520.
10. Carvlin MJ, Arger PH, Kundel HL, et al. Use of Gd-DTPA and fast gradient-echo and spin-echo MR imaging to demonstrate renal function in the rabbit. Radiology 1989;170:705-711.
11. Low RN. Current uses of gadolinium chelates for clinical magnetic resonance imaging examination of the liver. Top Magn Reson Imaging 1998;9:141-166.
12. Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR 1998;170:1005-1013.
13. Laing AD, Gibson RN. MRI of the liver. J Magn Reson Imaging 1998;8:337-345.
14. Hawighorst H, Schoenberg SO, Knopp MV, et al. Hepatic lesions: morphologic and functional characterization with multiphase breath-hold 3D gadolinium-enhanced MR angiography - initial results. Radiology 1999;210:89-96.
15. Vittadini G, Felder E, Musu C, Tirone P. Preclinical profile of Gd-BOPTA. A liver-specific MRI contrast agent. Invest Radiol 1990; 25(suppl 1):S59-60.
16. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991;22:233-237; discussion 242.
17. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792.
18. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996;199:177-183.
19. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR 1992;158:887-892.
20. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67.
21. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology 1990;176: 61-64.
22. Cavagna F, Dapra M, Maggioni F, et al. Gd-BOPTA/Dimeg: experimental disease imaging. Magn Reson Med 1991;22:329-333; discussion 343-346.
23. Vogl TJ. Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-728.
24. Holman ER, van Rossum AC, Doesburg T, et al. Assessment of acute myocardial infarction in man with magnetic resonance imaging and the use of a new paramagnetic contrast agent gadolinium-BOPTA. Magn Reson Imaging 1996;14:21-29.
25. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998;33:798-809.
26. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.